Clinical trial · Observational
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
NCT00477425CI-TRIAL-00027568withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Signed Informed Consent Form * Enrollment in one of a list of certain randomized, controlled bevacizumab trials Exclusion Criteria: * Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD) * Congenital long QT syndrome * Family history of long QT syndrome * Clinically significant bradycardia (defined as \< 50 beats/minute)
References
Publications (0)
Data not yet available
No reference posted for this study.